Hisamitsu Pharmaceutical launches 15 billion yen buyback program

Hisamitsu Pharmaceutical purchased 1.77 million shares for 7.1 billion yen on July 11, 2025, as part of its shareholder return strategy.

The company's board approved a larger buyback program allowing acquisition of up to 3 million shares (4.09% of outstanding shares) for a maximum 15 billion yen through December 2025.

Hisamitsu plans to return over 50 billion yen to shareholders between fiscal years 2027-2031.